UK to Legalize Medicinal Cannabis

Patients will be able to access the drug with a prescription, and there are no plans to allow for recreational use.

Written byCatherine Offord
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Doctors in the UK will be able to prescribe medicinal cannabis to patients starting in the fall of this year, according to a government announcement made yesterday (July 26). The move follows national debate over high-profile cases in which children with severe epilepsy were first denied, then allowed access to cannabis oil shown to ease the symptoms of the condition.

“Recent cases involving sick children made it clear to me that our position on cannabis-related medicinal products was not satisfactory,” Interior Minister Sajid Javid told reporters yesterday, according to Reuters. “Following advice from two sets of independent advisers, I have taken the decision to reschedule cannabis-derived medicinal products—meaning they will be available on prescription.”

Until now, cannabis has been considered a Schedule 1 substance, a legal classification that means the plant can be used by researchers with a license, but is not thought to have any therapeutic value. Yesterday’s announcement ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies